These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33590406)

  • 1. Prophylactic strategies to control chikungunya virus infection.
    Hucke FIL; Bestehorn-Willmann M; Bugert JJ
    Virus Genes; 2021 Apr; 57(2):133-150. PubMed ID: 33590406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and Promising Antivirals Against Chikungunya Virus.
    Hucke FIL; Bugert JJ
    Front Public Health; 2020; 8():618624. PubMed ID: 33384981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chikungunya virus infections: time to act, time to treat.
    Abdelnabi R; Neyts J; Delang L
    Curr Opin Virol; 2017 Jun; 24():25-30. PubMed ID: 28414993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development.
    de Lima Cavalcanti TYV; Pereira MR; de Paula SO; Franca RFO
    Viruses; 2022 May; 14(5):. PubMed ID: 35632709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular epidemiology, evolution and phylogeny of Chikungunya virus: An updating review.
    Lo Presti A; Cella E; Angeletti S; Ciccozzi M
    Infect Genet Evol; 2016 Jul; 41():270-278. PubMed ID: 27085290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chikungunya virus: recent advances in epidemiology, host pathogen interaction and vaccine strategies.
    Deeba F; Islam A; Kazim SN; Naqvi IH; Broor S; Ahmed A; Parveen S
    Pathog Dis; 2016 Apr; 74(3):. PubMed ID: 26657109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chikungunya virus infection: molecular biology, clinical characteristics, and epidemiology in Asian countries.
    Khongwichit S; Chansaenroj J; Chirathaworn C; Poovorawan Y
    J Biomed Sci; 2021 Dec; 28(1):84. PubMed ID: 34857000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine and Therapeutic Options To Control Chikungunya Virus.
    Powers AM
    Clin Microbiol Rev; 2018 Jan; 31(1):. PubMed ID: 29237708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutics and vaccines against chikungunya virus.
    Ahola T; Couderc T; Ng LF; Hallengärd D; Powers A; Lecuit M; Esteban M; Merits A; Roques P; Liljeström P
    Vector Borne Zoonotic Dis; 2015 Apr; 15(4):250-7. PubMed ID: 25897811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.
    Weger-Lucarelli J; Chu H; Aliota MT; Partidos CD; Osorio JE
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2970. PubMed ID: 25058320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral therapeutics for chikungunya virus.
    Ghildiyal R; Gabrani R
    Expert Opin Ther Pat; 2020 Jun; 30(6):467-480. PubMed ID: 32249636
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease.
    Julander JG; Anderson N; Haese N; Andoh T; Streblow DN; Cortez P; Carter K; Marniquet X; Watson H; Mandron M
    Antiviral Res; 2022 Jun; 202():105295. PubMed ID: 35339583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
    Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHIKV strains Brazil (wt) and Ross (lab-adapted) differ with regard to cell host range and antiviral sensitivity and show CPE in human glioblastoma cell lines U138 and U251.
    Hucke FIL; Bestehorn-Willmann M; Bassetto M; Brancale A; Zanetta P; Bugert JJ
    Virus Genes; 2022 Jun; 58(3):188-202. PubMed ID: 35347588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Chikungunya in the Americas.
    Yactayo S; Staples JE; Millot V; Cibrelus L; Ramon-Pardo P
    J Infect Dis; 2016 Dec; 214(suppl 5):S441-S445. PubMed ID: 27920170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Strategies for Inhibition of Chikungunya Infection.
    Subudhi BB; Chattopadhyay S; Mishra P; Kumar A
    Viruses; 2018 May; 10(5):. PubMed ID: 29751486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.
    Tretyakova I; Hearn J; Wang E; Weaver S; Pushko P
    J Infect Dis; 2014 Jun; 209(12):1882-90. PubMed ID: 24585894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent development in the strategies projected for chikungunya vaccine in humans.
    Goyal M; Chauhan A; Goyal V; Jaiswal N; Singh S; Singh M
    Drug Des Devel Ther; 2018; 12():4195-4206. PubMed ID: 30573950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.
    Silva LA; Dermody TS
    J Clin Invest; 2017 Mar; 127(3):737-749. PubMed ID: 28248203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.